ArticleWorld journal of hepatology2013
Management of hepatocellular carcinoma: Enlightening the gray zones.
Article in World journal of hepatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Review
- Folliculin depletion results in liver cell damage and cholangiocarcinoma through MiT/TFE activation.Cell death and differentiation · 2025Article
- Budd-Chiari Syndrome Management: Controversies and Open Issues.Diagnostics (Basel, Switzerland) · 2022Article
- Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management.Journal of gastrointestinal oncology · 2021Review
- Determinants of pain in advanced HCC patients recieving hepatic artery infusion chemotherapy.Investigational new drugs · 2021Article
- Evidence-based medicine and Management of Hepatocellular Carcinoma in Thalassemia.BMC gastroenterology · 2020Article
- Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence.BMC gastroenterology · 2020Review
- Mitotic quiescence in hepatic cancer stem cells: An incognito mode.Oncology reviews · 2020Article
- Polyphyllin II inhibits liver cancer cell proliferation, migration and invasion through downregulated cofilin activity and the AKT/NF-κB pathway.Biology open · 2020Article
- External Radiation versus Internal Radiation for Patients with Advanced Unresectable HCC -A SEER Based Study.Journal of Cancer · 2019Article
- Hepatocellular Carcinoma in β-Thalassemia Patients: Review of the Literature with Molecular Insight into Liver Carcinogenesis.International journal of molecular sciences · 2018Review
- Intrahepatic recurrence of single nodular hepatocellular carcinoma after surgical resection: an analysis by segmental distribution.ANZ journal of surgery · 2018Article
- Timing of Transjugular Intrahepatic Portosystemic Shunt for Budd-Chiari Syndrome: An Italian Hepatologist's Perspective.Journal of translational internal medicine · 2017Article
- Hepatitis B virus infection in undocumented immigrants and refugees in Southern Italy: demographic, virological, and clinical features.Infectious diseases of poverty · 2017Article
- Clock gene Per2 as a controller of liver carcinogenesis.Oncotarget · 2016Article
- HCC-Associated Liver Transplantation - Where Are the Limits and What Are the New Regulations?Visceral medicine · 2016Review
- Hepatocellular carcinoma: a review.Journal of hepatocellular carcinoma · 2016Review
- Diagnosis and treatment of hepatocellular carcinoma: An update.World journal of hepatology · 2015Review
- Use of magnetic resonance imaging to monitor iron overload.Hematology/oncology clinics of North America · 2014Review
- Prognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: current status and future prospects.World journal of gastroenterology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Management of hepatocellular carcinoma (HCC) has been continuously evolving during recent years. HCC is a worldwide clinical and social issue and typically a complicates cirrhosis. The incidence of HCC is increasing, not only in the general population of patients with cirrhosis, but particularly in some subgroups of patients, like those with human immunodeficiency virus infection or thalassemia. Since a 3% annual HCC incidence has been estimated in cirrhosis, a bi-annual screening is generally suggested. The diagnostic criteria of HCC has recently had a dramatic evolution during recent years. HCC diagnosis is now made only on radiological criteria in the majority of the cases. In the context of cirrhosis, the universally accepted criteria for HCC diagnosis is contrast enhancement in arterial phase and washout in venous/late phase at imaging, the so called "typical pattern". However, recently updated guidelines slightly differ in diagnostic criteria. Apart from liver transplantation, the only cure of both HCC and underlying liver cirrhosis, all the other treatments have to match with higher rate of HCC recurrence. The latter can be classified into curative (resection and percutaneous ablation) and palliative treatments. The aim of this paper was to review the current knowledge on management of HCC and to enlighten the areas of uncertainty.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.